Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a GFP tag.
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
GFP
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 530 nm
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Immobilized Fluorescent Human SSTR2 Full Length Protein (VLP) (Cat. No. SS2-HF2G3) at 1 μg/mL (100 μL/well) can bind Anti-SSTR2 Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The mean peak Radius of VLP is 55-75 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Price(USD) : $620.00
Price(USD) : $1235.00
Price(USD) : $4305.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pasireotide Pamoate | Approved | Novartis Pharma Ag | Signifor lar | United States | Acromegaly | Recordati Rare Diseases Inc | 2014-12-15 | Acromegaly; Gigantism; Cushing Syndrome; Carcinoid Tumor; Neuroendocrine Tumors; Pituitary ACTH Hypersecretion; Meningioma | Details | |
Lutetium (177Lu) oxodotreotide | Lu-DOTATATE; Lutetium (177Lu) DOTA-TATE; 177Lu-DOTATATE; [Lu-177]-DOTATATE; AAA-601; F-1515; XTR-008; [177Lu]Lu-DOTA-TATE | Approved | Advanced Accelerator Applications Sa | Lutathera | EU | Neuroendocrine Tumors | Advanced Accelerator Applications Sa | 2017-09-26 | Prostatic Neoplasms; Carcinoid Heart Disease; Meningioma; Paraganglioma; Gastroenteropancreatic neuroendocrine tumor; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Neuroendocrine; Pituitary Neoplasms; Medullary thyroid cancer (MTC); Neuroblastoma; Liver Neoplasms; Breast Neoplasms; Neuroendocrine Tumors; Malignant Carcinoid Syndrome; Pancreatic neuroendocrine tumors (pNET); Pancreatic Neoplasms; Adenoma, Islet Cell; Bronchial Neoplasms; Carcinoid Tumor; Pheochromocytoma; Leiomyosarcoma | Details |
Vapreotide Acetate | RC-160; BMY-41606 | Approved | Debiopharm Group | Sanvar, Docrised, Sanvar IR, Sanvar SR | Acromegaly; Pancreatic Neoplasms; Hypertension, Portal; Neuroendocrine Tumors; Hemorrhage; Diarrhea; Intraoperative Complications; Postoperative Complications; Esophageal and Gastric Varices; Crohn Disease | Details | ||||
Pasireotide Diaspartate | SOM-230; SOM-230C; SOM-320 | Approved | Novartis Pharma Ag | Signifor, 丝尼芬 | EU | Cushing Syndrome | Recordati Rare Diseases Inc | 2012-04-24 | Hyperinsulinism; Cysts; Uveal melanoma; Multiple Myeloma; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Alcoholism; Nelson Syndrome; Pituitary Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thyroid Neoplasms; Thymoma; Cluster Headache; Gastroenteropancreatic neuroendocrine tumor; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Prolactinoma; Meningioma; Pancreatic Neoplasms; ACTH Syndrome, Ectopic; Congenital Hyperinsulinism; Cushing Syndrome; Dumping Syndrome; Carcinoid Tumor; Renal Insufficiency; Insulinoma; Hypoglycemia; Acromegaly; Liver Cirrhosis; Neoplasms; Hormone-Resistant Prostate Neoplasms; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Pituitary ACTH Hypersecretion; Neuroendocrine Tumors | Details |
Ga-68 Edotreotide | SMT-487; [68Ga]DOTATOC; 90Y-DOTATOC | Approved | Advanced Accelerator Applications Sa | SomaKit TOC, Gallium Dotatoc Ga 68, TOCscan | EU | Diagnostic agents; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors | Advanced Accelerator Applications Sa | 2016-12-08 | Medulloblastoma; Multiple Endocrine Neoplasia Type 1; Carcinoid Tumor; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Neuroblastoma; Pituitary Neoplasms; Diagnostic agents; Paraganglioma; Meningioma; von Hippel-Lindau Disease; Somatostatinoma | Details |
Gallium (68Ga) oxodotreotide | 68Ga-DOTA-TATE; 68-Ga-DOTA-TATE | Approved | Advanced Accelerator Applications Sa | Netspot | United States | Neuroendocrine Tumors | Aaa Usa Inc | 2016-06-01 | Carcinoid Tumor; Pheochromocytoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Neuroendocrine Tumors; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Thyroid Neoplasms; Carcinoma, Hepatocellular; von Hippel-Lindau Disease; Paraganglioma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Paltusotine | CRN-00808 | Phase 3 Clinical | Crinetics Pharmaceuticals Inc | Acromegaly; Malignant Carcinoid Syndrome; Neuroendocrine Tumors | Details |
Lutetium-177 labelled edotreotide | ITM-11 | Phase 3 Clinical | Universitaetsspitals Basel, Itm Solucin Gmbh | Solid tumours; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Central Nervous System Neoplasms; Thymus Neoplasms; Carcinoma, Neuroendocrine; Lung Neoplasms; Lymphoma; Gastroenteropancreatic neuroendocrine tumor | Details |
Actinium-225 Dotate | RYZ-101; 225Ac-DOTATATE | Phase 3 Clinical | RayzeBio Inc | Carcinoid Tumor; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Metastatic breast cancer; Gastroenteropancreatic neuroendocrine tumor | Details |
Lutetium-177 DOTA satoreotide | [177Lu]LuSSO110; 177Lu-DOTA- JR11; 177Lu-satoreotide; 177Lu-IPN01072; 177Lu-IPN-1072; 177Lu SSO 110; OPS-201; 177LU-OPS 201 | Phase 2 Clinical | OctreoPharm Sciences GmbH | Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Breast Neoplasms; Meningioma | Details |
Nendratareotide uzatansine | BTP-277; PEN-221 | Phase 2 Clinical | Tarveda Therapeutics Inc | Small Cell Lung Carcinoma; Neuroendocrine Tumors; Carcinoma, Neuroendocrine | Details |
Yttrium 90-labelled edotreotide | SMT-487-[90Y]; DOTATOC-[90Y] | Phase 2 Clinical | The University Of Iowa, Novartis Pharma Ag | Solid tumours; Medulloblastoma; Skin Melanoma; Pheochromocytoma; Carcinoid Tumor; Adenoma, Islet Cell; Neoplasms; Central Nervous System Neoplasms; Neuroendocrine Tumors; Neuroblastoma; Breast Neoplasms; Sarcoma; Brain Neoplasms; Lymphoma; Lung Neoplasms; Meningioma | Details |
ZT-01 | ZT 01; ZT-01 | Phase 2 Clinical | Tulane University, York University, University Of Toronto, Toronto | Diabetes Mellitus, Type 1; Hypoglycemia | Details |
Re-188 P 2045 | P2045; BAY-865284; Rhenium-188 P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188-P-2045 | Phase 2 Clinical | Bayer AG | Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung | Details |
[203-Pb] VMT-NET | [203-Pb] VMT-NET | Phase 2 Clinical | Perspective Therapeutics Inc | Head and Neck Neoplasms; Pheochromocytoma; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Paraganglioma | Details |
64Cu-SarTate | Phase 2 Clinical | Clarity Pharmaceuticals Ltd, University Of Melbourne | Neuroendocrine Tumors; Neuroblastoma; Meningioma | Details | |
68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neuroendocrine Tumors; Lung Neoplasms; Meningioma | Details |
[225Ac]Ac-DOTATATE | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Neuroendocrine Tumors | Details | |
[99mTc]Tc-TECANT1 | Phase 1 Clinical | Ljubljana University Medical Centre, Medical University Of Innsbruck, Narodowe Centrum Badan Jadrowych, Jagiellonian University Sylff Fellows Association | Neuroendocrine Tumors | Details | |
161Tb-DOTA-LM3 | 161Tb-DOTA-LM3 | Phase 1 Clinical | University Hospital Basel | Neuroendocrine Tumors; Gastroenteropancreatic neuroendocrine tumor | Details |
44Sc-edotreotide | 44Sc-edotreotide; 44Sc-DOTA-[3-Tyr]-octreotide; Sc44-DOTATOC | Clinical | Zentralklinik Bad Berka | Diagnostic agents | Details |
225AcDOTA-LM3 | 225AcDOTA-LM3 | Clinical | CURANOSTICUM Wiesbaden-Frankfurt | Pancreatic neuroendocrine tumors (pNET) | Details |
This web search service is supported by Google Inc.